InMed Pharmaceuticals (INM) Net Income towards Common Stockholders (2021 - 2026)

InMed Pharmaceuticals' Net Income towards Common Stockholders history runs 6 years deep, the most recent figure standing at -$174585.0 for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders fell 224.14% year-over-year to -$174585.0 in Q1 2026; TTM through Mar 2026 was -$5.2 million, a 16.05% increase from a year earlier, with the FY2025 full-year figure at -$8.2 million, down 6.34% from the prior year.
• Net Income towards Common Stockholders climbed to -$174585.0 in Q1 2026 per INM's latest filing, from -$2.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$53861.0 in Q1 2025 and bottomed at -$7.9 million in Q2 2022.
• The 5-year median for Net Income towards Common Stockholders is -$1.9 million (2024), against an average of -$2.1 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 473.57% in 2024 and jumped 96.87% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$2.1 million in 2022, then climbed by 29.55% to -$1.5 million in 2023, then sank by 74.2% to -$2.6 million in 2024, then climbed by 21.23% to -$2.0 million in 2025, then jumped by 91.39% to -$174585.0 in 2026.
• Per Business Quant, the three latest INM Net Income towards Common Stockholders figures stand at -$174585.0 (Q1 2026), -$2.0 million (Q4 2025), and -$1.7 million (Q3 2025).